Charles Morgan is currently the Head of Regulatory CMC at Denali Therapeutics leading the development and execution of CMC regulatory strategies across Denali’s clinical portfolio for the treatment of neurodegenerative diseases. Previous roles included technical regulatory team leader and protein formulation scientist at Genentech including contributions to the development and approval of POLIVY® (polatuzumab vedotin). At Genzyme, he focused on the analytical characterization, biophysical and biochemical analysis of glycoprotein therapeutics. Charles has two decades of experience in the development of proteins as therapeutics following postdoctoral research at Yale University on protein amyloids and a doctorate from the University of Oxford in protein folding.